KUALA LUMPUR: Bintai Kinden Corp Bhd has entered right into a collaboration with Institut Jantung Negara Sdn Bhd (IJN) to develop a Covid-19 vaccine in Malaysia.
In a press release, the group mentioned it had entered right into a collaborative settlement with the nationwide coronary heart institute to ascertain a partnership within the business growth of the Ii-Key-SARS-CoV-2 coronavirus (Covid-19) vaccine.
It mentioned the collaboration was based mostly on an current partnership between the corporate’s subsidiary Bintai Healthcare Sdn Bhd (“BHSB”), Generex Biotechnology Corp and NuGenerex Immuno-Oncology Inc.
Below the cooperative settlement, Bintai Kinden might be chargeable for the introduction of the Covid-19 vaccine in Malaysia whereas IJN will carry out and lead the medical assessments of the vaccine as required by the Well being Ministry.
“After Generex has obtained the complete Meals and Drug Administration (FDA) approval on the vaccine and offers full documentation to BHSB, BHSB will start the registration course of to Nationwide Pharmaceutical Regulatory Company (NPRA) of Malaysia for the vaccine,” mentioned Bintai Kinden govt director Azri Azerai.